From Science to Patients – Ideas Become Treatments at CureVac

CureVac already has several active ingredients in research and (pre-)clinical development for the treatment of cancer and for protection against infectious diseases. Until today, CureVac has tested its mRNA-based products in several clinical studies and has received clinical trial approvals in 10 European countries, Asia and the US.

Our success is tangible, inspiring us to continue on our path every day.

CureVac's Pipeline

RNA-based Cancer Therapies
Research
Pre-clinic
Phase I
Phase II
Phase III
Sponsor
NSCLC (RNActive®, Combination BI 1361849 / CV9202 with CPI)
Phase I
Boehringer Ingelheim & Ludwig Cancer Research
NSCLC (RNActive®, Combination BI 1361849 / CV9202 with CPI)
Pre-clinic
Boehringer Ingelheim
Superficial tumors (TLR-/RIG-I agonist CV8102, i.t., combination + CPI)
Phase I
CureVac

CureVac’s TLR-/RIG-I agonist (CV8102) is a potent immunomodulator designed to expand the effects of immuno-oncology treatments and prophylactic vaccines for the prevention of infectious diseases.

Current Status: Phase I

Targeted tumors are melanoma, squamous cell carcinoma of skin, head and neck, adenoid cystic carcinoma.

For further information on this study please visit clinicaltrials.gov.

Hepatocellular carcinoma (RNAdjuvant® / multipeptide vaccine)
Phase I
Hepavac
Superficial tumors (RNArt® / RNAntibody®)
Pre-clinic
CureVac
Different indications (RNActive® Neoantigens in comb. with CPI)
Pre-clinic
Lilly
Further undisclosed mRNA cancer therapies
Research
CureVac
RNA-based Prophylactic Vaccines (RNActive®)
Research
Pre-clinic
Phase I
Phase II
Phase III
Sponsor
Rabies (CV7201, protamine formulation)
Phase I
CureVac

CV7201 is an mRNA-based vaccine encoding the glycoprotein of rabies virus (RAV-G).

Current Status: Phase I

The study is designed to evaluate the safety and immunogenicity of CV7201 according to (1) dose level (2) route of injection and (3) injection schedule. Rabies-specific binding and neutralizing titers will be evaluated across different injection routes using an injection schedule of 0-7-28 and 0-28-56. Over 100 subjects have been enrolled at the University of Munich, Germany under the supervision of Dr. F.-J. von Sonnenburg.

For further information on this study please visit clinicaltrials.gov.

Rabies (CV7202, next generation formulation)
Pre-clinic
CureVac
Influenza (CV7301, next generation formulation)
Pre-clinic
CureVac
Diverse projects (i.e. Malaria, Influenza)
Research
Bill and Melinda Gates Foundation
RSV
Research
CureVac
HIV
Research
IAVI
Outbreak/ Emerging targets
Pre-clinic
CureVac
RNA-based Molecular Therapies
Research
Pre-clinic
Phase I
Phase II
Phase III
Sponsor
RNAntibody®
Pre-clinic
undisclosed
Ornithine transcarbamylase (OTC) deficiency
Pre-clinic
Arcturus
Rare Disease Enzyme Replacement (undisclosed target)
Research
CureVac
Gene-editing (liver)
Pre-clinic
CRISPR
Further undisclosed projects
Pre-clinic
CureVac